ADMA Biologics Faces Securities Fraud Lawsuit; Investors Can Join
ADMA Biologics has been named in a class action lawsuit alleging violations of securities laws. Investors are now invited to participate in the legal action.
National shareholder rights litigation firm Schall, Brown & Schwartz LLP (SBS) has announced a class action lawsuit against ADMA Biologics, Inc. (NASDAQ: ADMA). The suit alleges violations of federal securities laws.
According to the complaint, ADMA Biologics is accused of violating Sections 10(b) and 20(a) of the Securities Exchange Act. The company allegedly made false or misleading statements to investors regarding its business operations and financial condition.
SBS Law is seeking ADMA Biologics investors who suffered financial losses in the company's securities during specific periods to come forward. These investors may have the opportunity to serve as lead plaintiff in the lawsuit.
Further details regarding the lawsuit and the relevant time frame are available on the SBS Law website. ADMA Biologics has not yet issued a public statement concerning the litigation.